Screening strategies and predictive diagnostic tools for the development of new-onset diabetes mellitus after transplantation: an overview
Received 15 August 2012
Accepted for publication 12 September 2012
Published 26 October 2012 Volume 2012:5 Pages 379—387
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Phuong-Thu T Pham,1 Kari L Edling,2 Harini A Chakkera,3 Phuong-Chi T Pham,4 Phuong-Mai T Pham5
1Department of Medicine, Nephrology Division, Kidney Transplant Program, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 2Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 3Department of Medicine, Nephrology Division Kidney Transplant Program, Mayo Clinic Hospital, Phoenix, AZ, USA; 4Department of Medicine, Nephrology Division, UCLA-Olive View Medical Center, Sylmar, CA, USA; 5Department of Medicine, Greater Los Angeles, Veterans Administration Health Care System, CA, USA
Abstract: New-onset diabetes mellitus after transplantation (NODAT) is a serious and common complication following solid organ transplantation. NODAT has been reported in 2% to 53% of all solid organ transplants. Kidney transplant recipients who develop NODAT have variably been reported to be at increased risk of fatal and nonfatal cardiovascular events and other adverse outcomes including infection, reduced patient survival, graft rejection, and accelerated graft loss compared with those who do not develop diabetes. Limited clinical studies in liver, heart, and lung transplants similarly suggested that NODAT has an adverse impact on patient and graft outcomes. Early detection and management of NODAT must, therefore, be integrated into the treatment of transplant recipients. Studies investigating the best screening or predictive tool for identifying patients at risk for developing NODAT early after transplantation, however, are lacking. We review the clinical predictive values of fasting plasma glucose, oral glucose tolerance test, and A1C in assessing the risk for NODAT development and as a screening tool. Simple diabetes prediction models that incorporate clinical and/or metabolic risk factors (such as age, body mass index, hypertriglyceridemia, or metabolic syndrome) are also presented.
Keywords: new-onset diabetes after transplantation, impaired fasting glucose, impaired glucose tolerance, oral glucose tolerance test, NODAT screening, diabetes prediction models
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.